Dalteparin
Class
Anticoagulants
Subclass
Low molecular weight heparins
Substance name
Dalteparin sodium
Brand names
Fragmin®
Common formulations
Solution for injection
Dosage and administration
Adults patients
Treatment
VTE in patients with cancer • Extended treatment
Cerebral venous thrombosis • Off-label
PE • Off-label
VTE in patients with cancer • Off-label
VTE in pregnant females • Off-label
Adjunctive treatment
Adjunctive treatment for non-ST-elevation acute coronary syndrome
Prevention
DVT in patients with acute Illness
DVT in patients with cancer, during abdominal surgery
DVT, during abdominal surgery
DVT, during hip replacement
Arterial thromboembolism • Perioperative bridging of VKA therapy, during surgery • Off-label
Prosthetic valve thrombosis • Bridging • Off-label
VTE in patients with cancer • Off-label
VTE in pregnant females • Off-label
Indications for use
Labeled indications
Adults
Off-label indications
Adults
Safety risks
Boxed warnings
Epidural hematoma, spinal hematoma
Contraindications
Hypersensitivity to dalteparin or its components
Active major bleeding
History of heparin-induced thrombocytopenia
Warnings and precautions
Decreased platelet count
Gasping syndrome
Hemorrhage
Heparin-induced thrombocytopenia
Specific populations
Renal impairment
eGFR ≥ 30 mL/min/1.73 m²
eGFR < 30 mL/min/1.73 m²
Renal replacement therapy
Any modality
Hepatic impairment
Any severity
Pregnancy and breastfeeding
Pregnancy
All trimesters • Australia Category: C
Breastfeeding
Acceptable for use during breastfeeding.
Unknown drug levels in breastfed infants.
No overt adverse effects reported in breastfed infants.
Adverse reactions
Common 1-10%
Unknown frequency
Interactions
Drug(s)
Check Interactions
Reset
What did you think about this content?
Sign up for free to access the full drug resource